| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SGCB |
| Uniprot No | Q16585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-318aa |
| 氨基酸序列 | MAAAAAAAAEQQSSNGPVKKSMREKAVERRSVNKEHNSNFKAGYIPIDED RLHKTGLRGRKGNLAICVIILLFILAVINLIITLVIWAVIRIGPNGCDSM EFHESGLLRFKQVSDMGVIHPLYKSTVGGRRNENLVITGNNQPIVFQQGT TKLSVENNKTSITSDIGMQFFDPRTQNILFSTDYETHEFHLPSGVKSLNV QKASTERITSNATSDLNIKVDGRAIVRGNEGVFIMGKTIEFHMGGNMELK AENSIILNGSVMVSTTRLPSSSSGDQLGSGDWVRYKLCMCADGTLFKVQV TSQNMGCQISDNPCGNTH |
| 预测分子量 | 61 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SGCB(β-肌聚糖)重组蛋白研究的代表性文献摘要概括：
1. **"Recombinant expression and purification of human β-sarcoglycan in E. coli for muscular dystrophy studies"**
- 作者：Li, X. et al. (2016)
- 摘要：报道了在大肠杆菌系统中成功表达可溶性SGCB重组蛋白，并通过亲和层析纯化，验证其在体外细胞模型中修复肌细胞膜稳定性的功能。
2. **"Adeno-associated virus-mediated SGCB gene delivery restores sarcoglycan complex in limb-girdle muscular dystrophy models"**
- 作者：Wang, Y. & Chamberlain, J.R. (2019)
- 摘要：利用AAV载体递送重组SGCB基因至小鼠模型，证实其能有效恢复肌聚糖复合体结构并改善肌肉病理表型。
3. **"Structural characterization of β-sarcoglycan using cryo-EM reveals pathogenic mutation effects"**
- 作者：Nguyen, H.H. et al. (2021)
- 摘要：通过冷冻电镜解析SGCB蛋白三维结构，发现致病突变位点(如R91W)导致其与δ-sarcoglycan结合界面构象改变，影响复合体稳定性。
注：以上为模拟文献案例，实际文献需通过PubMed(https://pubmed.ncbi.nlm.nih.gov)或Web of Science检索确认。建议以"SGCB recombinant protein"、"beta-sarcoglycan gene therapy"为关键词查找最新研究。
**Background of SGCB Recombinant Protein**
Sarcoglycan beta (SGCB), a key component of the sarcoglycan complex, plays a critical role in maintaining the structural integrity of muscle cell membranes. This transmembrane protein is part of the dystrophin-glycoprotein complex (DGC), which stabilizes the sarcolemma during muscle contraction and protects against mechanical stress. Mutations in the *SGCB* gene are linked to limb-girdle muscular dystrophy type 2E (LGMD2E), a progressive disorder characterized by muscle weakness and degeneration.
The development of recombinant SGCB protein has been driven by the need to study its biological functions, disease mechanisms, and therapeutic potential. Recombinant SGCB is typically produced using expression systems such as *E. coli*, mammalian cells, or insect cells, enabling large-scale synthesis with high purity. These systems allow precise control over post-translational modifications, which are essential for proper protein folding and functionality.
Research utilizing SGCB recombinant protein has advanced understanding of its interactions within the DGC, particularly its role in anchoring the complex to the extracellular matrix and stabilizing signaling pathways. Additionally, recombinant SGCB serves as a vital tool for developing gene therapies, protein replacement strategies, and antibody-based diagnostics for LGMD2E. It is also used in high-throughput drug screening to identify molecules that restore sarcoglycan complex function or mitigate disease-related cellular stress.
Overall, SGCB recombinant protein bridges basic research and clinical applications, offering insights into muscle biology and paving the way for targeted therapies to address sarcoglycanopathies. Its continued study holds promise for improving outcomes in neuromuscular disorders. (Word count: 247)
×
